ALSO NOTED: YM BioSciences gets cancer drug approval in India; Takeda starts testing of diabetes treatment; and much more...

> YM BioSciences has received approval from India's Drug Controller General to market nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer. Release

> Takeda has announced that subsidiary Takeda Global Research & Development Center has kicked off Phase III testing of TAK-536, a potential type 2 diabetes treatment. Release

> Berlex is recalling a single lot of its intravenous X-ray contrast agent, Ultravist Injection, due serious safety concerns related to the presence of particulate matter in conjunction with crystallization. Report

> Eli Lilly and Alcon will co-promote ruboxistaurin mesylate (Arxxant)--a treatment for moderate to severe nonproliferative diabetic retinopathy--in the U.S and Puerto Rico. Release

And Finally... A report from the Institute of Medicine states that 1.5 million Americans are harmed or killed by due to medications errors. Article